LivaNova

SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer

Retrieved on: 
Monday, April 1, 2024
Cloud, Automation, HR, Forecasting, Growth, LivaNova, CFO, Health, The Company, Attitude, Software, MBA, Bethel University, FP, FDA, Heart failure, Management

EDEN PRAIRIE, MN, April 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Peter Sorensen as its new CFO. 

Key Points: 
  • He earned his BA in business administration from Bethel University and an MBA from the Herberger Business School at St.
  • “We are pleased to welcome Peter to SANUWAVE at this pivotal time in our growth plans,” said CEO Morgan Frank.
  • SANUWAVE’s trajectory is truly remarkable and I am eager to contribute my expertise to drive financial success and support the team’s realization of their innovative vision to deliver cutting edge wound care solutions that positively impact patients’ lives worldwide,” said Sorensen.
  • Sorensen begins work at SANUWAVE on April 1, 2024.

LivaNova to Announce First-Quarter 2024 Results

Retrieved on: 
Thursday, March 21, 2024
Research, General Health, Mental Health, Medical Devices, Hospitals, Health Technology, Surgery, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, PLC, Telephone, LIVN, LivaNova

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time).

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time).
  • The Company will release its first-quarter 2024 results prior to the call.
  • Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast.
  • A replay will be available on the LivaNova website for 90 days following the call.

Minneapolis Psychiatry Clinic Adds Vagus Nerve Stimulation as Non-Drug Therapy for Severe Depression

Retrieved on: 
Wednesday, March 20, 2024
Mental Health, Surgery, Medical Devices, Alternative Medicine, Health, Vagus nerve, Deep brain stimulation, Depression, DSM-IV codes, Brain, VNS, LivaNova, Vagus nerve stimulation, Patient, TMS, Mental health, Bipolar disorder, Skin, Ketamine, Transcranial magnetic stimulation, Medicare, FDA, CMS

Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.

Key Points: 
  • Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.
  • VNS has a 70% success rate when used for treatment resistant depression, meaning the patient hasn’t responded to traditional antidepressants.
  • VNS stimulates the vagus nerve, triggering its natural process of sending electrical pulses to the parts of the brain that control mood.
  • For more information about Vagus Nerve Stimulation and what to expect, visit Advanced Brain and Body Clinic’s VNS page .

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Retrieved on: 
Wednesday, March 20, 2024
Research, Mental Health, Medical Devices, FDA, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Principal, OSA, LivaNova, Obstructive sleep apnea, Somnolence, PLC, Patient, AHI, University, Trial of the century, LIVN, University of California, Randomized controlled trial, Safety, Probability, Food, Medical imaging

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation , has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation , has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.
  • This means there is a greater than 97.5% probability that the OSPREY trial will successfully meet its primary endpoint.
  • LivaNova notified the U.S. Food and Drug Administration (FDA) and its partner trial sites of this significant milestone for the OSPREY study.
  • “We are pleased to have achieved this positive milestone for the OSPREY study,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova.

Sleep Apnea Devices Market, Industry Trends and Global Forecasts, 2035

Retrieved on: 
Friday, March 15, 2024
Diagnosis, ResMed, Non-invasive ventilation, Sleep apnea, CPAP, Growth, Prevalence, APAP, LivaNova, Obstructive sleep apnea, Polysomnography, Ageing, Ventilation, Research, Overalls, Central sleep apnea, Woman, Hub, Interest, USD, Administration, Pharmaceutical industry

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.

Key Points: 
  • The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.
  • The global sleep apnea diagnostic devices market is categorized into polysomnography devices and home sleep apnea testing devices.
  • The market report features an extensive study of the current market landscape, sleep apnea devices market share, market size, market analysis, market forecast and future opportunities for the sleep apnea companies involved in the development of sleep apnea medical devices and sleep apnea drugs.
  • Sleep Apnea Devices Market Analysis: Sleep Apnea Therapeutic Devices Hold Majority Market Share
    The global sleep apnea devices market is estimated to be worth USD 13.5 billion in 2024.

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029

Retrieved on: 
Wednesday, March 6, 2024
Cardiology, Biotechnology, FDA, Health, Mental Health, Medical Devices, Research, Hospitals, Surgery, Science, Clinical Trials, The International Stock Exchange, Financial services, Person, Trustee, LIVN, Sale, Exercise, LivaNova, European Economic Area, Risk, PLC, Observation, Finance, Security (finance)

Prior to December 15, 2028, the notes will be convertible only upon satisfaction of certain conditions.

Key Points: 
  • Prior to December 15, 2028, the notes will be convertible only upon satisfaction of certain conditions.
  • If the initial purchasers of the notes exercise their option to purchase additional notes, LivaNova expects to enter into additional capped call transactions with the option counterparties.
  • The cash exchangeable senior notes were issued by LivaNova USA, Inc. and are guaranteed by LivaNova.
  • In connection with the issuance of the cash exchangeable senior notes, LivaNova USA, Inc. entered into capped call transactions with certain financial institutions.

LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes

Retrieved on: 
Monday, March 4, 2024
FDA, Health Technology, Finance, Surgery, Professional Services, Mental Health, General Health, Medical Devices, Hospitals, Clinical Trials, Cardiology, Science, Biotechnology, Health, Research, The International Stock Exchange, Financial services, Person, Trustee, LIVN, Sale, Exercise, LivaNova, European Economic Area, Risk, PLC, Observation, Security (finance)

The interest rate, conversion rate and other terms of the notes are to be determined upon pricing of the offering.

Key Points: 
  • The interest rate, conversion rate and other terms of the notes are to be determined upon pricing of the offering.
  • If the initial purchasers of the notes exercise their option to purchase additional notes, LivaNova expects to enter into additional capped call transactions with the option counterparties.
  • The cash exchangeable senior notes were issued by LivaNova USA, Inc. and are guaranteed by LivaNova.
  • In connection with the issuance of the cash exchangeable senior notes, LivaNova USA, Inc. entered into capped call transactions with certain financial institutions.

LivaNova to Present at the Barclays Global Healthcare Conference

Retrieved on: 
Monday, March 4, 2024
Research, General Health, Mental Health, Medical Devices, Hospitals, Health Technology, Surgery, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, LIVN, PLC, LivaNova, Webcast, Conference

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida.
  • The presentation will take place at 10:45 a.m. Eastern Time on Tuesday, March 12.
  • The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events .
  • A replay will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event.